Navigation Links
Challenges in Entecavir Drug Treatment

According to a new report in the New England Journal of Medicine,treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal.

the researchers reported that a patient infected with both hepatitis B and HIV who was treated with entecavir developed a mutant strain of HIV that is resistant to the antiviral drugs lamivudine and emtricitabine. Entecavir is manufactured by Bristol-Myers Squibb and is marketed under the trade name Baraclude.

The research team was led by Chloe Thio and Howard Hughes Medical Institute investigator Robert Siliciano, both at The Johns Hopkins University School of Medicine. The analyses reported in the paper were performed by lead authors Moira McMahon, Benjamin Jilek, and Timothy Brennan in the Siliciano laboratory.

The groups initial report of the findings in February, 2007, at the Conference on Retroviruses and Opportunistic Infections led the drugs manufacturer, Bristol-Myers Squibb, to change its product labeling to warn of the potential for HIV drug resistance, notify prescribing physicians, and inform the Food and Drug Administration.

The United States Department of Health and Human Services now recommends against using entecavir as the first option in treating hepatitis B in co-infected patients who are not already using drugs to suppress HIV. More than 4 million people worldwide are believed to be infected with both viruses.

The scientists emphasized that finding drug resistance in this setting underscores the need to test all antiviral drugs for anti-HIV activity before they are approved for use.

Entecavir is a chemically altered version of a chemical called a nucleoside. The drug blocks viral replication by plugging itself into a polymerase enzyme in the hepatitis B virus that helps produce new viral DNA.

However, the hepatitis B polymeras
'"/>




Page: 1 2

Related medicine news :

1. Australia Ready to Meet the Challenges of Bird Flu
2. Sexual Health Service Is Under Pressure and Faced With Financial Challenges
3. Abuja Challenges the Government
4. Nurses in South Africa Face Challenges
5. Bangladesh Progressing But Must Yet Face Challenges In Health Sector
6. Fresh Water, HIV Biggest of Indias Six Challenges: Chidambaram
7. New Study Challenges How Regulators Determine Risk
8. FDA Cites Challenges of Generic Biotech
9. Study Challenges Conventional Treatment of Traumatic Brain Injury
10. Challenges in Prostate Cancer Screening by Prostate Cancer Antigen
11. Advances in Treatment of Cataracts
Post Your Comments:
(Date:10/13/2008)...e-FirstCall/ -- Nutraceutical,International Corpor...Hough,President, and Cory McQueen, Vice President...e a presentation regarding the Company on Wednesda... Living Conference in,Boston, Massachusetts. The p...that day and will be web cast live on the followin...
(Date:10/13/2008)...mbination of low plasma levels of antioxidants and...th certain forms of the eye disease age-related ma... the October issue of Archives of Ophthalmology ,...ina is vulnerable to the damaging effects of light...the article. "While wavelengths in the UV radiatio...
(Date:10/13/2008)... Today,s autism research draws on a,variety of sci...agnetic,resonance imaging (fMRI) to neural develop... "Development and Brain Systems in Autism," 16 of,... present their latest,groundbreaking findings on t...udy that will continue to improve scientists, unde...
(Date:10/13/2008)... WITH THE VIPER RESPONDER LE SPECIAL E...STA, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Dir...I Holdings Inc. (Nasdaq: DEIX ), has joined,the f...f Responder LE,Special Edition 2-Way Vehicle Secur...Susan G. Komen for the Cure. For each pink Respond...
Breaking Medicine News(10 mins):Health News:Nutraceutical to Present at Canaccord Adams Healthy Living Conference 2Health News:Nutraceutical to Present at Canaccord Adams Healthy Living Conference 3Health News:Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease 2Health News:Carnegie Mellon International Autism Symposium to Feature Groundbreaking Research, Oct. 17-18 2Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 2Health News:Supporting Susan G. Komen for the Cure(R) During National Breast Cancer Awareness Month 3
...voiced concerns about an outbreak of mumps that ha... have contacted the infection on airline // flight... childhood illness, which was all but wiped out wi...mps and rubella vaccine. "The state of Iowa has...
...dearly, like deleting important files or leaving g...n. According to the published work of US scientist... more active after "costly" mistakes. This may hel...tudy examined the brains of 12 healthy adults usin...
...at alcoholism by taking it just once a month. Alke...Vivitrol, an injectable form of naltrexone adminis.... ReVia by Barr Pharmaceuticals Inc. is how the p...y. This drug would be freely available by June end...
...ed Front for Children: Global Efforts to Combat Se...' // to be held on the 21st of April at the Univer...curb sex trafficking, at a global level. The event...hington S.E., Minneapolis, and is free and open to...
Other Medicine News:Health News:Costly mistakes help better understand OCD: obsessive compulsive disorder 2
(Date:10/13/2008)... Expansion of Genomic DNA from Multiple Cancer... Disease Studies, ANN ARBOR, Mich., Oct. 13 /PRN... an agreement with SAIC-Frederick to amplify DNA s...con Genomics was selected to amplify and standardi...amples from cancer patients. The Rubicon,GenomePle...
(Date:10/10/2008)... WASHINGTON and MENLO PARK, Calif., Oct. 10 /...T ) today announced that it plans to present,long-...clinical trials next,week at the Cardiovascular Re...theter Cardiovascular Therapeutics (TCT) meeting i...rospective studies designed to investigate,the saf...
(Date:10/10/2008)... PLEASANTON, Calif., Oct. 10 /- ... has been authorized to affix the CE (Conformite,E... Antares(TM) Coronary,Stent System, a unique main ...or near coronary bifurcations., Representing the ...es(TM) system has potential use in a quarter of th...
(Date:10/9/2008)... Scripps Translational Science Institute, Nav...eaking health study, SAN DIEGO, Oct. 9 /PRNewswir...research leaders have joined forces in a first-of-...mpact of personal genetic testing,on people who ch...potential,risk for developing certain diseases., ...
Breaking Medicine Technology:Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5FDA Panel to Consider Over the Counter Statin 8183 1FDA Panel to Consider Over the Counter Statin 8183 2FDA Panel to Consider Over the Counter Statin 8183 3FDA Panel to Consider Over the Counter Statin 8183 4FDA Panel to Consider Over the Counter Statin 8183 5BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends 8181 1BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends 8181 2Shire plc 3A Board Changes 2173 1Shire plc 3A Board Changes 2173 2Shire plc 3A Board Changes 2173 3Shire plc 3A Board Changes 2173 4Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update 2170 1
...is Examines Impact of Pain on Sleep Interference, ...-- Data from a,pooled analysis of three studies su...c nerve damage, or diabetic peripheral neuropathy,...mprovements in,both average daily pain and night p...d sleep interference than in those patients,taking...
...ay 03, 2007 /PRNewswire/ -- Bayer HealthCare,Pharm...inical,studies with Betaseron(R) (interferon beta-...f Neurology,s (AAN) 59th Annual Meeting,demonstra...igh,patient satisfaction with treatment in patient... , "Collectively, these studies highlight the impo...
Other Medicine Technology:Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 2Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 3Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 4Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 5Data Suggest Cymbalta Reduced Severity of Night Pain in Patients,with Diabetic Nerve Pain 6Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 2Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 3Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 4
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: